Jazz Pharmaceuticals flags $755 million Actio charge, about $11 a share hit to Q3 EPS

Jazz Pharmaceuticals warned on Monday that a roughly $755 million charge tied to its acquisition of Actio Biosciences will reduce its third-quarter earnings by about $11.00 per share.

In an 8-K, the drugmaker said its GAAP and non-GAAP results for the quarter will include a pre-tax expense of about $755 million for acquired in-process research and development, or IPR&D. That is the accounting for the value of drug programs that are still in development.

Because the charge is not tax deductible, Jazz estimates it will cut both GAAP EPS and non-GAAP adjusted EPS by about $11.00 for the quarter.

About the deal

Jazz completed its acquisition of Actio Biosciences on Sept. 15, 2026, according to the filing.

Because the expense is counted in both GAAP and non-GAAP results, it will weigh on the company's adjusted earnings as well as its reported earnings.

Still preliminary

Jazz cautioned that its third-quarter results are not final and are still going through closing procedures. Actual results could differ from the estimate. The company did not release any other third-quarter figures in the filing.

Key facts

• Charge: about $755 million pre-tax, acquired IPR&D
• Tax treatment: not deductible
• EPS impact: about $11.00 to both GAAP and non-GAAP adjusted EPS
• Related deal: Actio Biosciences, closed Sept. 15, 2026

Sources

1. Jazz Pharmaceuticals plc, Form 8-K (Item 2.02), filed Oct. 26, 2026 (accession 0001628280-26-067275)

This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.

Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.